EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Effectiveness of R‐ CHOP versus R‐ CHOEP for treatment of young patients with high‐risk diffuse large B‐cell lymphoma: A Danish observational population‐based study

Rasmus Rask Kragh Jørgensen iD, Lasse Hjort Jakobsen, Sandra Eloranta iD, Karin E Smedby, Robert Schou Pedersen, Judit M Jørgensen, Michael Roost Clausen iD, Peter Brown, Anne Ortved Gang, Inger-Lise Gade, Thomas Stauffer Larsen, Mats Jerkeman und 1 weitere

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14275 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Rasmus Rask Kragh Jørgensen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols, Vincristine, Cyclophosphamide. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Danish Cancer Society, Kræftens Bekæmpelse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Etoposide to standard R‐CHOP is used for high‐risk diffuse large B‐cell lymphoma (DLBCL) in some countries. Due to the lack of randomized trials, a real‐world data study using matching methods was used to test the potential effectiveness of R‐CHOEP over R‐CHOP. Patients and Methods This study included patients from the Danish Lymphoma Register diagnosed between 2006 and 2020 at the age of 18–60 years with de novo DLBCL and age‐adjusted IPI ≥2. R‐CHOEP treated patients were matched 1:1 without replacement to R‐CHOP treated patients using a hybrid exact and genetic matching technique. Primary endpoints were progression‐free survival (PFS) and overall survival (OS).

Results

In total, 396 patients were included; 213 received R‐CHOEP and 183 received R‐CHOP. Unadjusted 5‐year PFS and OS for R‐CHOEP were 69% (95% Confidence intervals [CI]; 63%–76%) and 79% (CI;73%–85%) versus 62% (CI;55%–70%) and 76% (CI;69%–82%) for R‐CHOP (log‐rank test, PFS p = .25 and OS p = .31). A total of 127 patients treated with R‐CHOEP were matched to 127 patients treated with R‐CHOP. Matching‐adjusted 5‐year PFS and OS were 65% (CI; 57%–74%) and 79% (CI; 72%–84%) for R‐CHOEP versus 63% (CI; 55%–73%) and 79% (CI;72%–87%) for R‐CHOP (log‐rank test, PFS p = .90 and OS p = .63).

Conclusion

The present study did not confirm superiority of R‐CHOEP over R‐CHOP for young patients with high‐risk DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsVincristineCyclophosphamideDoxorubicinRituximabEtoposidePrednisoneHumansDenmarkFemaleMaleAdultMiddle AgedYoung AdultAdolescentTreatment OutcomeRegistriesPopulation SurveillancePrednisolone

Stichwörter der Autor:innen

DLBCLR‐CHOP vs R‐CHOEPlymphomaoptimizing treatment outcomereal world datatoxicity after treatmenttreatment of high‐risk patients

Substanzen

VincristineCyclophosphamideDoxorubicinRituximabEtoposidePrednisoneR-CHOP protocolPrednisolone

Autor:innen und Institutionen

  • Department of Hematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.
  • Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden.
  • Department of Hematology, Gødstrup Hospital, Herning, Denmark.
  • Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Hematology, Vejle Hospital, Vejle, Denmark.

ORCID-Profile: Rasmus Rask Kragh Jørgensen, Sandra Eloranta, Michael Roost Clausen

Förderung

  • Danish Cancer Society
  • Kræftens Bekæmpelse

Zitieren

APA

Rask Kragh Jørgensen, R., Jakobsen, L. H., Eloranta, S., Smedby, K. E., Pedersen, R. S., Jørgensen, J. M., Clausen, M. R., Brown, P., Gang, A. O., Gade, I. L., Larsen, T. S., Jerkeman, M., & El-Galaly, T. C. (2024). Effectiveness of R‐ CHOP versus R‐ CHOEP for treatment of young patients with high‐risk diffuse large B‐cell lymphoma: A Danish observational population‐based study. European Journal of Haematology. https://doi.org/10.1111/ejh.14275

Vancouver

Rask Kragh Jørgensen R, Jakobsen LH, Eloranta S, Smedby KE, Pedersen RS, Jørgensen JM, et al. Effectiveness of R‐ CHOP versus R‐ CHOEP for treatment of young patients with high‐risk diffuse large B‐cell lymphoma: A Danish observational population‐based study. European Journal of Haematology. 2024. doi:10.1111/ejh.14275

BibTeX
@article{RaskKraghJrgensen2024,
  author = {Rask Kragh Jørgensen, Rasmus and Jakobsen, Lasse Hjort and Eloranta, Sandra and Smedby, Karin E and Pedersen, Robert Schou and Jørgensen, Judit M and Clausen, Michael Roost and Brown, Peter and Gang, Anne Ortved and Gade, Inger-Lise and Larsen, Thomas Stauffer and Jerkeman, Mats and El-Galaly, Tarec Christoffer},
  title = {Effectiveness of R‐ CHOP versus R‐ CHOEP for treatment of young patients with high‐risk diffuse large B‐cell lymphoma: A Danish observational population‐based study},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14275}
}
Kostenlos starten →